Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial

Yawen Wang, Mingzhi Zhang, Wei Song, Qingqing Cai, Liling Zhang, Xiuhua Sun, Liqun Zou, Huilai Zhang, Lili Wang, Hongwei Xue, Yawen Wang, Mingzhi Zhang, Wei Song, Qingqing Cai, Liling Zhang, Xiuhua Sun, Liqun Zou, Huilai Zhang, Lili Wang, Hongwei Xue

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a common type of peripheral T-cell lymphoma (PTCL) with a poor prognosis, and an effective first-line therapy is lacking. Chidamide is a selective histone deacetylase inhibitor and has been approved by the China Food and Drug Administration for relapsed or refractory PTCL. We conducted a multicenter phase II clinical trial combining chidamide with prednisone, etoposide, and thalidomide (CPET regimen) for a total of eight cycles in untreated AITL patients in China. The primary objectives were the overall response rate (ORR) and complete remission (CR) rate after eight cycles of the CPET regimen. The secondary endpoints were progression-free survival (PFS) and safety. Of the 71 enrolled patients, 51 completed the eight cycles of the CPET regimen. The ORR and CR of the 51 patients were 90.2 and 54.9%, respectively. After a median follow-up of 11.4 months (95% confidence interval [CI], 9.9-17.0), the median PFS of the 51 patients was 42.6 months (95% CI, 27.7-not reached) and the median overall survival (OS) was not reached. The 2-year PFS rate and OS rate were 66.5 and 82.2%, respectively. Sixty-eight patients received at least one cycle of CPET regimen and were included as the safety assessment population. The most common grade 3/4 adverse event was neutropenia (n = 22, 32.3%). Twelve patients showed treatment-related infections and recovered from antibiotic therapy; the other adverse events were mostly mild and reversible. The oral CPET regimen is an effective, tolerable, and economical choice for untreated AITL in a Chinese population. This trial was registered in www.clinicaltrials.gov as NCT03273452.

Conflict of interest statement

The authors declare that there is no conflicts of interest.

© 2022 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier analysis of overall survival (panel A, n = 68), progression‐free survival (panel B, n = 68) in all patients, and Kaplan–Meier analysis of the median duration of response (panel C, n = 57) [Color figure can be viewed at wileyonlinelibrary.com]

References

    1. Vose J, Armitage J, Weisenburger D. International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124‐4130.
    1. Lunning MA, Vose JM. Angioimmunoblastic T‐cell lymphoma: the many‐faced lymphoma. Blood. 2017;129(9):1095‐1102.
    1. Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429‐434.
    1. Chiba S, Sakata‐Yanagimoto M. Advances in understanding of angioimmunoblastic T‐cell lymphoma. Leukemia. 2020;34(10):2592‐2606.
    1. Broccoli A, Zinzani PL. Angioimmunoblastic T‐cell lymphoma. Hematol Oncol Clin North Am. 2017;31(2):223‐238.
    1. Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta‐analysis of front‐line Anthracycline‐based chemotherapy regimens for peripheral T‐cell lymphoma. ISRN Hematol 2011;2011:623924.
    1. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open‐label, pivotal phase II study of chidamide in relapsed or refractory peripheral T‐cell lymphoma. Ann Oncol. 2015;26(8):1766‐1771.
    1. Gottardi M, Danesin C, Canal F, et al. Complete remission induced by thalidomide in a case of angioimmunoblastic T‐cell lymphoma refractory to autologous stem cell transplantation. Leuk Lymphoma. 2008;49(9):1836‐1838.
    1. Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti GJ, Devereux S. Successful treatment of refractory angioimmunoblastic T‐cell lymphoma with thalidomide and dexamethasone. Haematologica 2006;91(8 Suppl):ECR44.
    1. Dogan A, Ngu LS, Ng SH, Cervi PL. Pathology and clinical features of angioimmunoblastic T‐cell lymphoma after successful treatment with thalidomide. Leukemia. 2005;19(5):873‐875.
    1. Cosenza M, Civallero M, Fiorcari S, et al. The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T‐cell lymphoma cell lines. Cancer Biol Ther. 2016;17(10):1094‐1106.
    1. Hopfinger G, Nösslinger T, Lang A, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol. 2014;93(3):459‐462.
    1. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005;4(12):1993‐2000.
    1. Johnston PB, Cashen AF, Nikolinakos PG, et al. Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first‐line treatment for patients with newly diagnosed peripheral T‐cell lymphoma. Exp Hematol Oncol. 2021;10(1):15.
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375‐2390.
    1. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059‐3068.
    1. Mourad N, Mounier N, Brière J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T‐cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008;111(9):4463‐4470.
    1. Li TT, Luo LT, Chen Y, Yang T, Hu JD. Clinical characteristics and prognosis in 84 patients with angioimmunoblastic T‐cell lymphoma: a single‐center analysis. Zhonghua Xue Ye Xue Za Zhi. 2020;41(11):915‐920.
    1. Hong H, Fang X, Huang H, Wang Z, Lin T, Yao H. The derived neutrophil‐to‐lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T‐cell lymphoma. Br J Haematol. 2020;189(5):908‐912.
    1. Delfau‐Larue MH, de Leval L, Joly B, et al. Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T‐cell lymphoma. A clinicobiological study of the GELA. Haematologica. 2012;97(10):1594‐1602.
    1. Lemonnier F, Safar V, Beldi‐Ferchiou A, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T‐cell lymphoma. Blood Adv. 2021;5(2):539‐548.
    1. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath‐1H) and CHOP chemotherapy as first‐line treatment of peripheral T‐cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316‐2323.
    1. Kim SJ, Yoon DH, Kang HJ, et al. Bortezomib in combination with CHOP as first‐line treatment for patients with stage III/IV peripheral T‐cell lymphomas: a multicentre, single‐arm, phase 2 trial. Eur J Cancer (Oxford, England: 1990). 2012;48(17):3223‐3231.
    1. Dupuis J, Morschhauser F, Ghesquières H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T‐cell lymphoma: a non‐randomised, phase 1b/2 study. Lancet Haematol. 2015;2(4):e160‐e165.
    1. Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30‐positive peripheral T‐cell lymphoma (ECHELON‐2): a global, double‐blind, randomised, phase 3 trial. Lancet (London, England). 2019;393(10168):229‐240.
    1. Butzmann ASK, Jangam D, Kumar J, et al. A comprehensive analysis of RHOA mutation positive and negative angioimmunoblastic T‐cell lymphomas by targeted deep sequencing, expression profiling and single cell digital image analysis. Int J Mol Med. 2020;46(4):1466‐1476.
    1. Palomero T, Couronné L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014;46(2):166‐170.
    1. Maura F, Agnelli L, Leongamornlert D, et al. Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma. Am J Hematol. 2019;94(6):628‐634.
    1. Moskowitz AJ. Practical treatment approach for angioimmunoblastic T‐cell lymphoma. J Oncol Pract. 2019;15(3):137‐143.
    1. Sakata‐Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171‐175.
    1. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T‐cell lymphoma. Blood. 2014;123(9):1293‐1296.
    1. Yao WQ, Wu F, Zhang W, et al. Angioimmunoblastic T‐cell lymphoma contains multiple clonal T‐cell populations derived from a common TET2 mutant progenitor cell. J Pathol. 2020;250(3):346‐357.
    1. Zhang P, Zhang M. Epigenetic alterations and advancement of treatment in peripheral T‐cell lymphoma. Clin Epigenetics. 2020;12(1):169.
    1. Quivoron C, Couronné L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25‐38.
    1. Mertsch SKO. The interplay between histone deacetylases and rho kinases is important for cancer and neurodegeneration. Cytokine Growth Factor Rev. 2017;37:29‐45.
    1. Tari GLF, Morschhauser F. Epigenetic focus on angioimmunoblastic T‐cell lymphoma: pathogenesis and treatment. Curr Opin Oncol. 2021;33(5):400‐405.
    1. Zhang YW, Wang Z, Xie W, et al. Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress. Mol Cell. 2017;65(2):323‐335.
    1. Sawas A, Ma H, Shustov A, et al. Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma. Leuk Lymphoma. 2020;61(8):2003‐2007.
    1. Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.
    1. O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T‐cell lymphoma: results of the pivotal phase II BELIEF (CLN‐19) study. J Clin Oncol. 2015;33(23):2492‐2499.
    1. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open‐label, phase II study of romidepsin in relapsed or refractory peripheral T‐cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631‐636.
    1. Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma. Hematol Oncol. 2017;35(4):914‐917.
    1. O'Connor OA, Falchi L, Lue JK, et al. Oral 5‐azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395‐1405.
    1. Wei S. Clinical analysis of Chidamide combined with etoposide, prednisone and thalidomide (C‐PET) regimen in the treatment of AITL patients [in Chinese]. Qingdao University Master's Thesis 2019.
    1. Koprinarova M, Schnekenburger M, Diederich M. Role of histone acetylation in cell cycle regulation. Curr Top Med Chem. 2016;16(7):732‐744.
    1. Luzhin AV, Velichko AK, Razin SV, Kantidze OL. Automated analysis of cell cycle phase‐specific DNA damage reveals phase‐specific differences in cell sensitivity to etoposide. J Cell Biochem. 2016;117(10):2209‐2214.
    1. Sionov RV, Spokoini R, Kfir‐Erenfeld S, Cohen O, Yefenof E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid‐induced apoptosis. Adv Cancer Res. 2008;101:127‐248.
    1. Raza S, Safyan RA, Lentzsch S. Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):846‐857.
    1. Zajączkowska R, Kocot‐Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy‐induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451‐1480.
    1. Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy. 1984;4(2):61‐73.
    1. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123‐2131.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅